1799 Stock Overview
Develops, manufactures, and sells active pharmaceutical ingredients and over-the-counter drug products in America. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Easywell Biomedicals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$60.90 |
| 52 Week High | NT$233.00 |
| 52 Week Low | NT$39.15 |
| Beta | 0.70 |
| 1 Month Change | -16.58% |
| 3 Month Change | -39.10% |
| 1 Year Change | 53.79% |
| 3 Year Change | 173.27% |
| 5 Year Change | 262.81% |
| Change since IPO | 35.32% |
Recent News & Updates
Shareholder Returns
| 1799 | TW Medical Equipment | TW Market | |
|---|---|---|---|
| 7D | -0.8% | 1.2% | 2.1% |
| 1Y | 53.8% | -5.7% | 28.0% |
Return vs Industry: 1799 exceeded the TW Medical Equipment industry which returned -6.1% over the past year.
Return vs Market: 1799 exceeded the TW Market which returned 28.8% over the past year.
Price Volatility
| 1799 volatility | |
|---|---|
| 1799 Average Weekly Movement | 10.3% |
| Medical Equipment Industry Average Movement | 4.0% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in TW Market | 7.8% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 1799's share price has been volatile over the past 3 months compared to the TW market.
Volatility Over Time: 1799's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of TW stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | n/a | James Aiping Lee | www.easywellbio.com |
Easywell Biomedicals, Inc., together with its subsidiaries, develops, manufactures, and sells active pharmaceutical ingredients and over-the-counter drug products in America. It operates through Drug Development and Other segments. The company develops TLX-001, an anti-cough medicine; TLX-005, an anti-urinary incontinence medicine; TLX-006 for treatment of breast cancer in PMS women; TLX-007 and TLX-004, an anti-depressant; TLX-008 for prevention of pneumocystis pneumonia; TLX-012 for treatment of epilepsy; TLX-017 for treatment of chronic angina; TLX-011 for treatment of inflammatory lesions of rosacea; TLX-015 a prevention and treatment medicine for postpartum hemorrhage; TLX-018, a hemorrhage treatment drug; TLX-030, an anti-inflammatory medicine; and TLX-024, an anticonvulsant.
Easywell Biomedicals, Inc. Fundamentals Summary
| 1799 fundamental statistics | |
|---|---|
| Market cap | NT$7.42b |
| Earnings (TTM) | -NT$120.87m |
| Revenue (TTM) | NT$483.81m |
15.3x
P/S Ratio-61.4x
P/E RatioIs 1799 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1799 income statement (TTM) | |
|---|---|
| Revenue | NT$483.81m |
| Cost of Revenue | NT$204.70m |
| Gross Profit | NT$279.11m |
| Other Expenses | NT$399.98m |
| Earnings | -NT$120.87m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.99 |
| Gross Margin | 57.69% |
| Net Profit Margin | -24.98% |
| Debt/Equity Ratio | 13.3% |
How did 1799 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/23 13:09 |
| End of Day Share Price | 2025/01/22 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Easywell Biomedicals, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|